Neurocrine Q2 net product sales up 17% to $682 million; INGREZZA guidance narrowed
Neurocrine Biosciences reported second-quarter 2025 net product sales of $682 million, up 17% year over year, and GAAP diluted earnings per share of $1.06 versus $0.63 a year earlier. The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion, lowering the top of the range, and said a Phase 3 study of valbenazine in schizophrenia did not meet its primary endpoint.
Key points
- Q2 2025 net product sales were $682 million: INGREZZA $624.4 million and CRENESSITY $53.2 million
- GAAP net income was $107.5 million ($1.06 per diluted share) versus $65.0 million ($0.63) in Q2 2024; non-GAAP EPS was $1.65 versus $1.63
- INGREZZA 2025 net product sales guidance narrowed to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion
- Company repurchased $18 million of stock in Q2 2025 and had $332 million remaining under its $500 million program as of June 30, 2025
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.